<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>RANKL inhibition &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/rankl-inhibition/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sun, 25 Oct 2026 06:34:44 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>RANKL inhibition &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Osteoporosis Drug Denosumab Outperforms Zoledronic Acid for Muscle Strength Over Three Years</title>
		<link>https://bioengineer.org/osteoporosis-drug-denosumab-outperforms-zoledronic-acid-for-muscle-strength-over-three-years/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sun, 25 Oct 2026 06:34:44 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[body composition]]></category>
		<category><![CDATA[computed tomography]]></category>
		<category><![CDATA[denosumab]]></category>
		<category><![CDATA[DXA]]></category>
		<category><![CDATA[grip strength]]></category>
		<category><![CDATA[osteoporosis]]></category>
		<category><![CDATA[osteosarcopenia]]></category>
		<category><![CDATA[physical performance]]></category>
		<category><![CDATA[Postmenopausal Women]]></category>
		<category><![CDATA[RANKL inhibition]]></category>
		<category><![CDATA[sarcopenia]]></category>
		<category><![CDATA[zoledronic acid]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=453107</guid>

					<description><![CDATA[A three-year prospective cohort study of 186 postmenopausal women with osteoporosis found that denosumab was associated with greater gains in grip strength, gait speed and chair-stand performance, along with more favourable CT-defined muscle remodelling, than zoledronic acid.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">453107</post-id>	</item>
	</channel>
</rss>
